ΠΠΎΠΌΠ°ΡΠ½Ρ ΡΡΠΎΡΡΠ½ΠΊΠ°IPN β’ EPA
add
Ipsen SA
ΠΠ°ΠΊΡΠΈΡΡΡ ΠΏΠΎΠΏΠ΅Ρ. Π΄Π½Ρ
118,70Β β¬
ΠΡΠ°ΠΏΠ°Π·ΠΎΠ½ ΡΡΠ½ Π·Π° Π΄Π΅Π½Ρ
117,90Β β¬ - 119,60Β β¬
ΠΡΠ°ΠΏΠ°Π·ΠΎΠ½ ΡΡΠ½ Π·Π° ΡΡΠΊ
99,70Β β¬ - 126,70Β β¬
Π ΠΈΠ½ΠΊΠΎΠ²Π° ΠΊΠ°ΠΏΡΡΠ°Π»ΡΠ·Π°ΡΡΡ
9,92Β ΠΌΠ»ΡΠ΄ EUR
Π‘Π΅Ρ. ΠΎΠ±ΡΡΠ³
61,12Β ΡΠΈΡ.
ΠΠΎΠ΅ΡΡΡΡΡΠ½Ρ ΡΡΠ½Π°/ΠΏΡΠΈΠ±ΡΡΠΎΠΊ
14,53
ΠΠΈΠ²ΡΠ΄Π΅Π½Π΄Π½ΠΈΠΉ ΠΏΡΠΈΠ±ΡΡΠΎΠΊ
1,01%
ΠΡΠ½ΠΎΠ²Π½Π° Π±ΡΡΠΆΠ°
EPA
ΠΠΎΠ²ΠΈΠ½ΠΈ ΡΠΈΠ½ΠΊΡ
Π€ΡΠ½Π°Π½ΡΠΎΠ²Ρ Π΄Π°Π½Ρ
ΠΠ²ΡΡ ΠΏΡΠΎ ΡΡΠ½Π°Π½ΡΠΎΠ²Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΈ
ΠΠΎΡ
ΡΠ΄
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄
(EUR) | ΡΠ΅ΡΠ². 2024β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
---|---|---|
ΠΠΎΡ
ΡΠ΄ | 875,90Β ΠΌΠ»Π½ | 7,93% |
ΠΠΏΠ΅ΡΠ°ΡΡΠΉΠ½Ρ Π²ΠΈΡΡΠ°ΡΠΈ | 557,05Β ΠΌΠ»Π½ | 8,31% |
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄ | 116,00Β ΠΌΠ»Π½ | 18,85% |
ΠΠ°ΡΠΆΠ° ΡΠΈΡΡΠΎΠ³ΠΎ ΠΏΡΠΈΠ±ΡΡΠΊΡ | 13,24 | 10,06% |
ΠΡΠΈΠ±ΡΡΠΎΠΊ Π½Π° Π°ΠΊΡΡΡ | β | β |
EBITDA | 240,85Β ΠΌΠ»Π½ | 0,31% |
ΠΡΠ΅ΠΊΡΠΈΠ²Π½Π° ΡΡΠ°Π²ΠΊΠ° ΠΏΠΎΠ΄Π°ΡΠΊΡ | 16,30% | β |
ΠΡΡ
Π³Π°Π»ΡΠ΅ΡΡΡΠΊΠΈΠΉ Π±Π°Π»Π°Π½Ρ
ΠΠ°Π³Π°Π»ΡΠ½Π° Π²Π°ΡΡΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ²
ΠΠ°Π³Π°Π»ΡΠ½Π° ΡΡΠΌΠ° Π·ΠΎΠ±ΠΎΠ²βΡΠ·Π°Π½Ρ
(EUR) | ΡΠ΅ΡΠ². 2024β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
---|---|---|
ΠΠΎΡΡΠ²ΠΊΠΎΠ²Ρ ΠΉ ΠΊΠΎΡΠΎΡΠΊΠΎΡΡΡΠΎΠΊΠΎΠ²Ρ Π²ΠΊΠ»Π°Π΄ΠΈ | 485,40Β ΠΌΠ»Π½ | 17,42% |
ΠΠ°Π³Π°Π»ΡΠ½Π° Π²Π°ΡΡΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ² | 6,55Β ΠΌΠ»ΡΠ΄ | 7,50% |
ΠΠ°Π³Π°Π»ΡΠ½Π° ΡΡΠΌΠ° Π·ΠΎΠ±ΠΎΠ²βΡΠ·Π°Π½Ρ | 2,50Β ΠΌΠ»ΡΠ΄ | -6,93% |
ΠΠ°Π³. ΡΡΠΌΠ° Π²Π»Π°ΡΠ½. ΠΊΠ°ΠΏΡΡΠ°Π»Ρ | 4,05Β ΠΌΠ»ΡΠ΄ | β |
Π¦ΠΈΡΠΊΡΠ»ΡΡΡΡ Π°ΠΊΡΡΡ | 82,86Β ΠΌΠ»Π½ | β |
P/B ΠΊΠΎΠ΅ΡΡΡΡΡΠ½Ρ | 2,43 | β |
Π Π΅Π½ΡΠ°Π±Π΅Π»ΡΠ½ΡΡΡΡ Π°ΠΊΡΠΈΠ²ΡΠ² | 6,13% | β |
Π Π΅Π½ΡΠ°Π±Π΅Π»ΡΠ½ΡΡΡΡ ΠΊΠ°ΠΏΡΡΠ°Π»Ρ | 8,85% | β |
ΠΡΠΎΡΠΎΠ²ΠΈΠΉ ΠΏΠΎΡΡΠΊ
Π§ΠΈΡΡΠ° Π·ΠΌΡΠ½Π° Π·Π°Π»ΠΈΡΠΊΡ Π³ΠΎΡΡΠ²ΠΊΠΈ
(EUR) | ΡΠ΅ΡΠ². 2024β―Ρ.info | ΠΠΌΡΠ½Π° Π·Π° ΡΡΠΊ |
---|---|---|
Π§ΠΈΡΡΠΈΠΉ Π΄ΠΎΡ
ΡΠ΄ | 116,00Β ΠΌΠ»Π½ | 18,85% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΠΎΠΏΠ΅ΡΠ°ΡΡΠΉ | 233,00Β ΠΌΠ»Π½ | 8,52% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΡΠ½Π²Π΅ΡΡΠΈΡΡΠΉ | -99,55Β ΠΌΠ»Π½ | 79,81% |
ΠΠΎΡΡΠ²ΠΊΠ° Π²ΡΠ΄ ΡΡΠ½Π°Π½ΡΡΠ²Π°Π½Π½Ρ | -159,10Β ΠΌΠ»Π½ | -51,45% |
Π§ΠΈΡΡΠ° Π·ΠΌΡΠ½Π° Π·Π°Π»ΠΈΡΠΊΡ Π³ΠΎΡΡΠ²ΠΊΠΈ | -26,00Β ΠΌΠ»Π½ | 93,10% |
ΠΡΠ»ΡΠ½ΠΈΠΉ Π³ΡΠΎΡΠΎΠ²ΠΈΠΉ ΠΏΠΎΡΡΠΊ | 15,01Β ΠΌΠ»Π½ | -89,78% |
ΠΠ½ΡΠΎΡΠΌΠ°ΡΡΡ
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
ΠΠ΅Π½Π΅ΡΠ°Π»ΡΠ½ΠΈΠΉ Π΄ΠΈΡΠ΅ΠΊΡΠΎΡ
ΠΠ°ΡΠ° Π·Π°ΡΠ½ΡΠ²Π°Π½Π½Ρ
1929
ΠΠ΅Π±-ΡΠ°ΠΉΡ
ΠΡΠ»ΡΠΊΡΡΡΡ ΠΏΡΠ°ΡΡΠ²Π½ΠΈΠΊΡΠ²
5Β 325